Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
13 août 2024 07h15 HE
|
Mural Oncology, Inc.
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
31 juil. 2024 07h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juil. 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
05 juin 2024 16h15 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 juin 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h00 HE
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 07h00 HE
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered...